These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 8628089)

  • 1. Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays.
    Graf P; Hallén H
    Laryngoscope; 1996 May; 106(5 Pt 1):605-9. PubMed ID: 8628089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzalkonium chloride in a decongestant nasal spray aggravates rhinitis medicamentosa in healthy volunteers.
    Graf P; Hallén H; Juto JE
    Clin Exp Allergy; 1995 May; 25(5):395-400. PubMed ID: 7553241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers.
    Hallén H; Graf P
    Clin Exp Allergy; 1995 May; 25(5):401-5. PubMed ID: 7553242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity.
    Graf P
    Rhinology; 1996 Mar; 34(1):9-13. PubMed ID: 8739860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment.
    Graf P; Hallén H
    ORL J Otorhinolaryngol Relat Spec; 1997; 59(1):39-44. PubMed ID: 9104748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of benzalkonium chloride on the nasal mucosa: allergic rhinitis and rhinitis medicamentosa.
    Graf P
    Clin Ther; 1999 Oct; 21(10):1749-55. PubMed ID: 10566570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis.
    Graf P; Enerdal J; Hallén H
    Arch Otolaryngol Head Neck Surg; 1999 Oct; 125(10):1128-32. PubMed ID: 10522506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity.
    Graf P; Hallén H; Juto JE
    Acta Otolaryngol; 1995 Jan; 115(1):71-5. PubMed ID: 7762389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis].
    Dorn M; Hofmann W; Knick E
    HNO; 2003 Oct; 51(10):794-9. PubMed ID: 14523532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decongestion effect and rebound swelling of the nasal mucosa during 4-week use of oxymetazoline.
    Graf P; Juto JE
    ORL J Otorhinolaryngol Relat Spec; 1994; 56(3):157-60. PubMed ID: 7515487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between objective nasal mucosal swelling and estimated stuffiness during long-term use of vasoconstrictors.
    Graf P; Juto JE
    ORL J Otorhinolaryngol Relat Spec; 1994; 56(6):334-9. PubMed ID: 7530821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate effect of benzalkonium chloride in decongestant nasal spray on the human nasal mucosal temperature.
    Lindemann J; Leiacker R; Wiesmiller K; Rettinger G; Keck T
    Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):357-61. PubMed ID: 15270822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhinitis medicamentosa: aspects of pathophysiology and treatment.
    Graf P
    Allergy; 1997; 52(40 Suppl):28-34. PubMed ID: 9353558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of decongestive nosedrops on human respiratory mucosa in vitro.
    Berg OH; Lie K; Steinsvåg SK
    Laryngoscope; 1994 Sep; 104(9):1153-8. PubMed ID: 7520965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of benzalkonium chloride on histamine H1 receptor mRNA expression in nasal epithelial cells.
    Kawabata M; Ohori J; Kurono Y
    Auris Nasus Larynx; 2016 Dec; 43(6):685-8. PubMed ID: 26946996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibition of granulocyte phagocytosis by various components of nasal drops.
    Håkansson B; Linder C; Ohlsson K; Tegner H; Toremalm NG
    Pharmacol Toxicol; 1989 Aug; 65(2):89-91. PubMed ID: 2478992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhinitis medicamentosa: a review of causes and treatment.
    Graf P
    Treat Respir Med; 2005; 4(1):21-9. PubMed ID: 15725047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal.
    Graf PM; Hallén H
    Am J Rhinol; 1997; 11(1):67-72. PubMed ID: 9065350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions.
    Marple B; Roland P; Benninger M
    Otolaryngol Head Neck Surg; 2004 Jan; 130(1):131-41. PubMed ID: 14726922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.
    Watanabe H; Foo TH; Djazaeri B; Duncombe P; Mackay IS; Durham SR
    Rhinology; 2003 Sep; 41(3):167-74. PubMed ID: 14579657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.